Latest News

Germany to pump €1bn into breakthrough innovation

German Research Minister Anja Karliczek and Economics Minister Peter Altmaier make a joint statement on the founding of the Agency for Jump Innovations following the meeting of the Federal Cabinet. © BMBF / Hans-Joachim Rickel


by tg

Germany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.

The German agency precede EU plans to create a similar EU agency within its next research framework programme starting in 2021. The agency will be funded with roughly €1bn over 10 years.

The move is intented to keep value creation in Germany.  The idea for such an agency is lent from the US agency DARPA (Defense Advanced Research Projects Agency), which was founded by President Dwight D. Eisenhower in the 1950ies to support commercialisation of groundbreaking inventions such as the Internet, GPS or driverless vehicles. Besides Germany, Sweden and Switzerland have already established innovation agencies for non-military purposes. 

The German agency is set to start next year. According to Germany’s minister for economics, Peter Altmaier, a first call will seek for 3 to 4 promising artificial intelligence projects.

Sanofi gets the EU’s ok for caplacizumab

The life-threatening, autoimmune-based blood clotting disorder leads to  severe thrombocytopenia, microangiopathic hemolytic anemia,...

ReViral raises US$55m

ReViral focusses on infections caused by the Respiratory Syncytial Virus (RSV). It is the most important respiratory pathogen, with 30 million...

Researchers remyelinate neurons

Peripheral nerves of patients with Charcot–Marie–Tooth disease 1A (CMT1A) display aberrant myelination during postnatal development, followed by...

Pharming receives complete response letter from FDA

In 2017, Pharming filed an sBLA to the FDA in order to expand the label of its recombinantly produced C1 esterase inhibitor Ruconest to prophylaxis...

IMI to spur on antibiotics research amidst big pharma pullback

The new IMI AMR Accelerator aims to progress the development of new treatments and vaccines for resistant bacterial infections. It “represents a...

Nanobiotix signs €40m deal with EIB

The agreement will run for five years and will enable the nanomedicine company to accelerate both the development of NBTXR3 clinical trial in the...

Roche and Affimed in US$5bn cancer deal

Under the deal, the Heidelberg-based blood cancer specialist will licence its ROCK (Redirected Optimized Cell Killing) platform, which enables...